Enzon Pharmaceuticals, Inc. Logo

Enzon Pharmaceuticals, Inc.

ENZN

(2.2)
Stock Price

0,12 USD

2.2% ROA

2.94% ROE

7.27x PER

Market Cap.

7.517.939,00 USD

0% DER

0% Yield

3976.92% NPM

Enzon Pharmaceuticals, Inc. Stock Analysis

Enzon Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Enzon Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.21x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE falls within an average range (1.51%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (1.5%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Enzon Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Enzon Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Enzon Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Enzon Pharmaceuticals, Inc. Revenue
Year Revenue Growth
1983 0
1984 0 0%
1985 0 0%
1986 100.000 100%
1987 100.000 0%
1988 300.000 66.67%
1989 2.700.000 88.89%
1990 2.500.000 -8%
1991 2.400.000 -4.17%
1992 5.700.000 57.89%
1993 8.400.000 32.14%
1994 14.800.000 43.24%
1995 15.800.000 6.33%
1996 12.700.000 -24.41%
1997 12.700.000 0%
1998 14.600.000 13.01%
1999 13.200.000 -10.61%
2000 17.017.797 22.43%
2001 31.587.709 46.13%
2002 75.804.746 58.33%
2003 146.406.000 48.22%
2004 169.571.000 13.66%
2005 0 0%
2006 185.653.000 100%
2007 185.601.000 -0.03%
2008 196.938.000 5.76%
2009 184.622.000 -6.67%
2010 97.865.000 -88.65%
2011 48.072.000 -103.58%
2012 42.600.000 -12.85%
2013 34.493.000 -23.5%
2014 31.173.000 -10.65%
2015 17.456.000 -78.58%
2016 8.377.000 -108.38%
2017 8.379.000 0.02%
2018 6.918.000 -21.12%
2019 207.000 -3242.03%
2020 52.000 -298.08%
2021 701.000 92.58%
2022 26.000 -2596.15%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Enzon Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1983 0
1984 200.000 100%
1985 300.000 33.33%
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 17.700.000 100%
1995 12.100.000 -46.28%
1996 10.100.000 -19.8%
1997 8.500.000 -18.82%
1998 8.700.000 2.3%
1999 6.800.000 -27.94%
2000 8.382.772 18.88%
2001 13.051.714 35.77%
2002 18.426.860 29.17%
2003 20.969.000 12.12%
2004 34.769.000 39.69%
2005 0 0%
2006 43.521.000 100%
2007 56.507.000 22.98%
2008 58.089.000 2.72%
2009 70.126.000 17.16%
2010 57.018.000 -22.99%
2011 41.106.000 -38.71%
2012 21.005.000 -95.7%
2013 2.715.000 -673.66%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Enzon Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1983 0
1984 500.000 100%
1985 1.100.000 54.55%
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 25.439.000 100%
2011 17.281.000 -47.21%
2012 14.475.000 -19.39%
2013 8.843.000 -63.69%
2014 2.383.000 -271.09%
2015 2.150.000 -10.84%
2016 1.679.000 -28.05%
2017 1.371.000 -22.47%
2018 1.063.000 -28.97%
2019 1.180.000 9.92%
2020 1.357.000 13.04%
2021 1.170.000 -15.98%
2022 1.058.000 -10.59%
2023 900.000 -17.56%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Enzon Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1983 0
1984 -500.000 100%
1985 -1.000.000 50%
1986 -2.000.000 50%
1987 -3.000.000 33.33%
1988 -5.200.000 42.31%
1989 -10.400.000 50%
1990 -13.600.000 23.53%
1991 -15.000.000 9.33%
1992 -30.500.000 50.82%
1993 -23.400.000 -30.34%
1994 -14.300.000 -63.64%
1995 -5.800.000 -146.55%
1996 -6.600.000 12.12%
1997 -3.540.000 -86.44%
1998 -2.820.000 -25.53%
1999 -5.400.000 47.78%
2000 -8.673.931 37.74%
2001 2.865.686 402.68%
2002 31.514.957 90.91%
2003 17.131.000 -83.96%
2004 60.363.000 71.62%
2005 0 0%
2006 17.161.000 100%
2007 24.116.000 28.84%
2008 20.193.000 -19.43%
2009 3.230.000 -525.17%
2010 13.451.000 75.99%
2011 -3.359.000 500.45%
2012 13.938.000 124.1%
2013 23.701.000 41.19%
2014 28.790.000 17.68%
2015 19.812.000 -45.32%
2016 6.752.000 -193.42%
2017 7.008.000 3.65%
2018 5.855.000 -19.69%
2019 -973.000 701.75%
2020 -1.305.000 25.44%
2021 -469.000 -178.25%
2022 -1.032.000 54.55%
2023 -900.000 -14.67%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Enzon Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1983 0
1984 0 0%
1985 0 0%
1986 200.000 100%
1987 200.000 0%
1988 500.000 60%
1989 1.700.000 70.59%
1990 1.700.000 0%
1991 2.000.000 15%
1992 6.600.000 69.7%
1993 9.900.000 33.33%
1994 15.400.000 35.71%
1995 15.400.000 0%
1996 11.300.000 -36.28%
1997 8.900.000 -26.97%
1998 11.000.000 19.09%
1999 8.900.000 -23.6%
2000 12.129.440 26.62%
2001 27.723.425 56.25%
2002 69.727.292 60.24%
2003 117.885.000 40.85%
2004 122.585.000 3.83%
2005 0 0%
2006 135.532.000 100%
2007 130.623.000 -3.76%
2008 135.236.000 3.41%
2009 137.106.000 1.36%
2010 88.773.000 -54.45%
2011 47.031.000 -88.75%
2012 31.224.000 -50.62%
2013 34.493.000 9.48%
2014 31.173.000 -10.65%
2015 17.456.000 -78.58%
2016 8.377.000 -108.38%
2017 8.379.000 0.02%
2018 6.918.000 -21.12%
2019 207.000 -3242.03%
2020 52.000 -298.08%
2021 701.000 92.58%
2022 26.000 -2596.15%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Enzon Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1983 0
1984 -600.000 100%
1985 -1.100.000 45.45%
1986 -1.700.000 35.29%
1987 -2.300.000 26.09%
1988 -4.400.000 47.73%
1989 -5.000.000 12%
1990 -8.000.000 37.5%
1991 -12.000.000 33.33%
1992 -28.200.000 57.45%
1993 -24.600.000 -14.63%
1994 -16.500.000 -49.09%
1995 -6.300.000 -161.9%
1996 -5.200.000 -21.15%
1997 -4.600.000 -13.04%
1998 -3.600.000 -27.78%
1999 -4.900.000 26.53%
2000 -6.306.464 22.3%
2001 11.525.064 154.72%
2002 45.806.343 74.84%
2003 45.726.000 -0.18%
2004 2.877.000 -1489.36%
2005 0 0%
2006 21.309.000 100%
2007 83.053.000 74.34%
2008 -2.715.000 3159.04%
2009 1.068.000 354.21%
2010 175.402.000 99.39%
2011 -20.763.000 944.78%
2012 -2.783.000 -646.07%
2013 18.150.000 115.33%
2014 28.795.000 36.97%
2015 21.637.000 -33.08%
2016 -1.126.000 2021.58%
2017 5.445.000 120.68%
2018 5.849.000 6.91%
2019 -979.000 697.45%
2020 -1.311.000 25.32%
2021 -469.000 -179.53%
2022 -186.000 -152.15%
2023 1.284.000 114.49%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Enzon Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1983 0
1984 0 0%
1985 0 0%
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 -1 0%
1991 -1 0%
1992 -1 100%
1993 -1 0%
1994 -1 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1 100%
2003 1 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 2 100%
2008 0 0%
2009 0 0%
2010 3 100%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Enzon Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1983 -100.000
1984 -900.000 88.89%
1985 -1.200.000 25%
1986 -1.700.000 29.41%
1987 -2.600.000 34.62%
1988 -4.200.000 38.1%
1989 -2.200.000 -90.91%
1990 -7.200.000 69.44%
1991 -11.700.000 38.46%
1992 -23.700.000 50.63%
1993 -26.500.000 10.57%
1994 -13.400.000 -97.76%
1995 -2.500.000 -436%
1996 -4.900.000 48.98%
1997 -5.100.000 3.92%
1998 -3.600.000 -41.67%
1999 -4.200.000 14.29%
2000 -7.684.149 45.34%
2001 3.471.346 321.36%
2002 8.244.039 57.89%
2003 49.295.000 83.28%
2004 30.661.000 -60.77%
2005 19.155.000 -60.07%
2006 -1.387.000 1481.04%
2007 65.368.000 102.12%
2008 22.621.000 -188.97%
2009 5.576.000 -305.69%
2010 20.648.000 72.99%
2011 -13.355.000 254.61%
2012 8.429.000 258.44%
2013 13.982.000 39.72%
2014 32.338.000 56.76%
2015 14.678.000 -120.32%
2016 2.599.000 -464.76%
2017 6.471.000 59.84%
2018 -978.000 761.66%
2019 6.905.000 114.16%
2020 -380.000 1917.11%
2021 -501.000 24.15%
2022 -659.000 23.98%
2023 426.000 254.69%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Enzon Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1983 -100.000
1984 -500.000 80%
1985 -1.000.000 50%
1986 -1.600.000 37.5%
1987 -2.400.000 33.33%
1988 -3.200.000 25%
1989 -1.200.000 -166.67%
1990 -6.300.000 80.95%
1991 -9.200.000 31.52%
1992 -18.800.000 51.06%
1993 -22.100.000 14.93%
1994 -12.600.000 -75.4%
1995 -2.100.000 -500%
1996 -4.800.000 56.25%
1997 -4.200.000 -14.29%
1998 -3.400.000 -23.53%
1999 -3.800.000 10.53%
2000 -6.915.734 45.05%
2001 5.553.967 224.52%
2002 30.746.780 81.94%
2003 60.520.000 49.2%
2004 37.091.000 -63.17%
2005 22.261.000 -66.62%
2006 43.307.000 48.6%
2007 100.431.000 56.88%
2008 30.507.000 -229.21%
2009 13.890.000 -119.63%
2010 22.615.000 38.58%
2011 -12.725.000 277.72%
2012 8.452.000 250.56%
2013 14.005.000 39.65%
2014 32.338.000 56.69%
2015 14.678.000 -120.32%
2016 2.599.000 -464.76%
2017 6.471.000 59.84%
2018 -978.000 761.66%
2019 6.905.000 114.16%
2020 -380.000 1917.11%
2021 -501.000 24.15%
2022 -659.000 23.98%
2023 426.000 254.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Enzon Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1983 0
1984 400.000 100%
1985 200.000 -100%
1986 100.000 -100%
1987 200.000 50%
1988 1.000.000 80%
1989 1.000.000 0%
1990 900.000 -11.11%
1991 2.500.000 64%
1992 4.900.000 48.98%
1993 4.400.000 -11.36%
1994 800.000 -450%
1995 400.000 -100%
1996 100.000 -300%
1997 900.000 88.89%
1998 200.000 -350%
1999 400.000 50%
2000 768.415 47.94%
2001 2.082.621 63.1%
2002 22.502.741 90.75%
2003 11.225.000 -100.47%
2004 6.430.000 -74.57%
2005 3.106.000 -107.02%
2006 44.694.000 93.05%
2007 35.063.000 -27.47%
2008 7.886.000 -344.62%
2009 8.314.000 5.15%
2010 1.967.000 -322.67%
2011 630.000 -212.22%
2012 23.000 -2639.13%
2013 23.000 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Enzon Pharmaceuticals, Inc. Equity
Year Equity Growth
1984 3.800.000
1985 2.800.000 -35.71%
1986 1.500.000 -86.67%
1987 14.500.000 89.66%
1988 10.300.000 -40.78%
1989 8.500.000 -21.18%
1990 25.100.000 66.14%
1991 49.800.000 49.6%
1992 30.700.000 -62.21%
1993 24.700.000 -24.29%
1994 10.600.000 -133.02%
1995 8.300.000 -27.71%
1996 12.900.000 35.66%
1997 8.501.000 -51.75%
1998 6.901.000 -23.19%
1999 25.600.000 73.04%
2000 120.962.164 78.84%
2001 138.989.225 12.97%
2002 190.495.143 27.04%
2003 291.584.000 34.67%
2004 291.544.000 -0.01%
2005 -83.970.000 447.2%
2006 -56.441.000 -48.77%
2007 36.573.000 254.32%
2008 41.661.000 12.21%
2009 53.283.000 21.81%
2010 331.857.000 83.94%
2011 197.181.000 -68.3%
2012 77.468.000 -154.53%
2013 5.255.000 -1374.18%
2014 29.603.000 82.25%
2015 18.089.000 -63.65%
2016 10.331.000 -75.09%
2017 9.144.000 -12.98%
2018 14.993.000 39.01%
2019 6.055.000 -147.61%
2020 47.820.000 87.34%
2021 47.351.000 -0.99%
2022 45.890.000 -3.18%
2023 2.515.000 -1724.65%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Enzon Pharmaceuticals, Inc. Assets
Year Assets Growth
1984 4.000.000
1985 2.900.000 -37.93%
1986 1.600.000 -81.25%
1987 14.700.000 89.12%
1988 11.200.000 -31.25%
1989 13.400.000 16.42%
1990 29.100.000 53.95%
1991 54.200.000 46.31%
1992 39.300.000 -37.91%
1993 33.900.000 -15.93%
1994 20.500.000 -65.37%
1995 19.200.000 -6.77%
1996 22.000.000 12.73%
1997 16.000.000 -37.5%
1998 13.700.000 -16.79%
1999 34.900.000 60.74%
2000 130.252.250 73.21%
2001 549.675.817 76.3%
2002 610.747.883 10%
2003 728.566.000 16.17%
2004 724.863.000 -0.51%
2005 341.345.000 -112.35%
2006 403.830.000 15.47%
2007 420.357.000 3.93%
2008 349.253.000 -20.36%
2009 332.749.000 -4.96%
2010 488.857.000 31.93%
2011 343.209.000 -42.44%
2012 199.781.000 -71.79%
2013 7.121.000 -2705.52%
2014 35.040.000 79.68%
2015 22.890.000 -53.08%
2016 11.271.000 -103.09%
2017 9.512.000 -18.49%
2018 15.510.000 38.67%
2019 6.478.000 -139.43%
2020 48.232.000 86.57%
2021 47.754.000 -1%
2022 47.589.000 -0.35%
2023 46.997.000 -1.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Enzon Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1984 200.000
1985 100.000 -100%
1986 100.000 0%
1987 200.000 50%
1988 900.000 77.78%
1989 4.900.000 81.63%
1990 4.000.000 -22.5%
1991 4.400.000 9.09%
1992 8.600.000 48.84%
1993 9.200.000 6.52%
1994 9.900.000 7.07%
1995 10.900.000 9.17%
1996 9.100.000 -19.78%
1997 7.499.000 -21.35%
1998 6.799.000 -10.3%
1999 9.300.000 26.89%
2000 9.290.086 -0.11%
2001 410.686.592 97.74%
2002 420.252.740 2.28%
2003 436.982.000 3.83%
2004 433.319.000 -0.85%
2005 425.315.000 -1.88%
2006 460.271.000 7.59%
2007 383.784.000 -19.93%
2008 307.592.000 -24.77%
2009 279.466.000 -10.06%
2010 157.000.000 -78%
2011 146.028.000 -7.51%
2012 122.313.000 -19.39%
2013 1.866.000 -6454.82%
2014 5.437.000 65.68%
2015 4.801.000 -13.25%
2016 940.000 -410.74%
2017 368.000 -155.43%
2018 517.000 28.82%
2019 423.000 -22.22%
2020 412.000 -2.67%
2021 403.000 -2.23%
2022 1.699.000 76.28%
2023 44.482.000 96.18%

Enzon Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0.01
Price to Earning Ratio
7.27x
Price To Sales Ratio
289.15x
POCF Ratio
7.67
PFCF Ratio
7.67
Price to Book Ratio
2.99
EV to Sales
-1501.5
EV Over EBITDA
37.57
EV to Operating CashFlow
-39.84
EV to FreeCashFlow
-39.84
Earnings Yield
0.14
FreeCashFlow Yield
0.13
Market Cap
0,01 Bil.
Enterprise Value
-0,04 Bil.
Graham Number
0.1
Graham NetNet
0.03

Income Statement Metrics

Net Income per Share
0.01
Income Quality
0.95
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
-0.02
Net Income per EBT
1.11
EBT Per Ebit
-0.89
Ebit per Revenue
-39.96
Effective Tax Rate
-0.11

Margins

Sales, General, & Administrative to Revenue
40.96
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
1
Operating Profit Margin
-39.96
Pretax Profit Margin
35.73
Net Profit Margin
39.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
1.23
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.01
Free CashFlow per Share
0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.46
Return on Tangible Assets
0.02
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,63
Book Value per Share
0,03
Tangible Book Value per Share
0.03
Shareholders Equity per Share
0.03
Interest Debt per Share
-0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
44.81
Current Ratio
115.48
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,05 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Enzon Pharmaceuticals, Inc. Dividends
Year Dividends Growth
2012 2
2013 2 0%
2015 1 0%
2016 0 0%
2017 0 0%
2019 0 0%

Enzon Pharmaceuticals, Inc. Profile

About Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

CEO
Mr. Richard L. Feinstein
Employee
0
Address
20 Commerce Drive
Cranford, 07016

Enzon Pharmaceuticals, Inc. Executives & BODs

Enzon Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Richard L. Feinstein
Chief Executive Officer, Chief Financial Officer & Company Secretary
70

Enzon Pharmaceuticals, Inc. Competitors